Company profile
Genprex, Inc.
NASDAQ:GNPXBiotechnology: Pharmaceutical Preparations
Drug pipeline (1)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| QUARATUSUGENE OZEPLASMID | phase1_2 | — | 3 | active |
Revenue is the latest reported period from SEC filings. A combination product's amount appears on each of its constituent assets, so those rows are not additive.
Clinical trials (4)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT05703971 | phase1_2 | recruiting | 2024-05-09 | 2026-06-01 | Genprex, Inc. | Quaratusugene Ozeplasmid (Reqorsa) and Atezolizumab Maintenance Therapy in ES-SCLC Patients |
| NCT04486833 | phase1_2 | recruiting | 2021-09-03 | 2028-03-01 | Genprex, Inc. | Quaratusugene Ozeplasmid (Reqorsa) and Osimertinib in Patients With Advanced Lung Cancer Who Progressed on Osimertinib |
| NCT05062980 | phase1 | terminated | 2022-03-30 | 2025-02-03 | Genprex, Inc. | Quaratusugene Ozeplasmid (Reqorsa) in Combination With Pembrolizumab in Previously Treated Non-Small Lung Cancer |
| NCT01455389 | phase1_2 | terminated | 2014-02-01 | 2016-10-27 | Genprex, Inc. | TUSC2-nanoparticles and Erlotinib in Stage IV Lung Cancer |
FDA applications (0)
No records yet.